Verici Dx publishes Circular and Notice of General Meeting

VRCI

Verici Dx Plc (LON:VRCI), a developer of advanced clinical diagnostics for organ transplant, has announced that a Circular has been published containing a notice of a general meeting to be held at the offices of Shoosmiths LLP at 1 Bow Churchyard, London, EC4M 9DQ at 11:30 a.m. on 22 June 2026.

The General Meeting is being held to ensure that the Company has sufficient authority to issue and allot new Ordinary Shares on a non-pre-emptive basis following the Fundraising announced on 5 June 2026.

The Circular and Notice of General Meeting has been posted to Shareholders and is available on the Company’s website at: https://vericidx.com/investors/documents/

Unless otherwise defined, all definitions used in this announcement will have the same meaning as described in the Circular.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

New BK virus research targets a major kidney transplant treatment gap

Oxford researchers are investigating whether HIF inhibitors could provide a new way to control BK virus in kidney transplant patients.

Verici Dx adds new proteomics revenue opportunity

Verici Dx has added a new proteomics service offering that could broaden revenue while making greater use of its existing US laboratory.

Verici Dx targets growing demand for kidney transplant diagnostics

Verici Dx is targeting the expanding kidney transplant diagnostics market as molecular surveillance becomes a larger part of post-transplant care.

Verici Dx strengthens commercial case for kidney transplant risk test

Verici Dx has published analysis showing its PTRA kidney transplant risk test could generate more than $191 million in US healthcare savings over two years.

Verici Dx secures Olink Certified Service Provider status

Verici Dx has achieved Olink Certified Service Provider status, expanding its proteomics assay capabilities at its CAP-certified and CLIA-accredited laboratory.

Verici Dx adds senior transplant experts to support clinical development

Verici Dx has expanded its Scientific Advisory Board with 14 senior transplant and clinical research specialists to support product development and adoption.

Search